性传播疾病

20110684单纯淋球菌感染与淋球菌混合其他病原体感染患者的治疗分析/李晶(上海普陀区医院皮肤科),张慧,钱伊弘…∥上海交通大学学报(医学版).-2010,30(7).-874~876收集32例单纯淋球菌感染患者和50例混合病原体感染患者(淋球菌合并沙眼衣原体或解脲脲原体或梅毒螺旋体感染)的临床资料,回顾患者经常规方案治疗的效果,比较单纯淋球菌感染与     

Ⅰ期梅毒合并淋球菌感染一例

目的:提醒临床医生注意,一期梅毒与淋病可以同一皮损处合并感染病人.方法:本文发现1例病人,通过详细询问病史,体格检查及实验室检查.结果:确定为1期梅毒合并淋球菌感染.结论:梅毒螺旋体和淋病奈瑟球菌,以同一皮损处为侵入门户,合并感染是存在的.     

尖锐湿疣患者合并解脲支原体沙眼衣原体和淋球菌感染的结果分析

对６５例确诊的尖锐湿疣患者，用ＰＣＲ法检测其泌尿生殖道的淋球菌、沙眼衣原体、解脲支原体。结果显示６５例患者中，有３５例合并淋球菌和（或）沙眼衣原体、解脲支原体感染，合并单一病原体感染者２５例，合并两种病原体混合感染者１０例。３５例合并感染者中，男１２例，女２３例。提示ＳＴＤ患者易合并（两种或两种以上）病原体感染，ＳＴＤ患者应进行全面的病原菌检查，以尽早发现隐匿性感染，及时进行针对性治疗     

尖锐湿疣患者合并解脲支原体沙眼衣原体和淋球菌感染的结果 …

对６５例确诊的尖锐湿疣患者，用ＰＣＲ法检测其泌尿生殖道的淋球菌、沙眼衣原体、解脲支原体。结果显示６５例患者中，有３５例合并淋球菌和（或）沙眼前原体、解脲支原体感染、合并单一病原体感染者２５列，合并两种病原体混合感染者１０例。３５例合并感染者中，男１２例，女２３例。提示ＳＴＤ患者易合并（两种或两种以上）病原体感染、ＳＴＤ患者应进行全面的病原菌检查，以尽早发现隐慝性感染，及时进行针对性治疗。     

多功能电离子治疗尖锐湿疣120例

我所于 1999年 7月～ 2 0 0 0年 7月用多功能电离子手术机治疗尖锐湿疣 (ＣＡ) 12 0例 ,并与疣脱欣 (辽宁华卫制药股份有限公司生产 )外用进行对比观察。现将结果报告如下 :1　临床资料　共 175例患者 ,男 5 4例 ,女 12 1例 ,均为门诊患者 ,按 1996年卫生防疫司制订的ＣＡ诊断标准确诊 ,妊娠、哺乳妇女除外。其中 14例合并淋球菌感染 ;2例同时合并淋球菌、梅毒螺旋体感染 ;9例合并支原体、衣原体感染 ;2 9例合并霉菌感染 ;1例皮肌炎患者。 89例性伴同时发病 ,2 3例有婚外性交史 ,但性伴未发病 ,6 4例病因不详。平均年龄 2 9岁 ,平均病程 45…     

男性性工作者尿液筛查沙眼衣原体和淋球菌及危险因素分析

目的:了解男性性工作者沙眼衣原体和淋球菌感染情况,为预防干预提供依据。方法:对男性性工作者采取知情同意进行问卷调查,取尿液进行生殖道沙眼衣原体及淋球菌检测。结果:95例男性性工作者,生殖道沙眼衣原体、淋球菌感染阳性率分别是12.6%、8.4%;两者混合感染2.1%。同性服务时间≤12个月、曾服兴奋剂、性交选择浴池和有固定异性性伴是其危险因素。结论:根据本研究结果有必要对男性性工作者的沙眼衣原体和淋球菌感染进行监测。     

国产阿奇霉素治疗STD_s84例疗效观察

我科于 1998年 11月至 1999年 12月使用国产阿奇霉素(山东齐鲁制药厂生产 ) ,治疗ＳＴＤｓ患者 84例取得满意疗效 ,现将结果报告如下 :1　临床资料 　 84例均为门诊病例 ,男 5 6例 ,女 2 8例 ,年龄 17～ 5 0岁 ,平均 2 8岁。就诊前一周均未全身应用抗生素。实验室检查采用分泌物涂片革兰染色镜检、淋球菌培养、立明Ｃ -Ｃ快速法 ,支原体培养 ,血清ＲＰＲ (定性定量 )ＴＰＨＡ确证以明确诊断。其中单纯性淋球菌感染 (ＧＵ) 34例 ,ＧＵ合并沙眼衣原体 (ＣＴ)双重感染 10例 ,ＧＵ合并解脲支原体 (ＵＵ)双重感染 9例 ,ＧＵ合并ＣＴ及ＵＵ三重感…     

323例泌尿生殖道衣原体感染合并淋菌及支原体分析

沙眼衣原体(CT)是引起非淋菌性尿道炎(NGU)及女性生殖系统感染的主要病原体。为了解沙眼衣原体合并淋球菌、支原体感染情况，我们于1997年6月～2002年9月，对于确诊为沙眼衣原体感染患者同时进行淋球菌(NG)、解脲支原体(UU)、人型支原体(MH)的检测，有完整资料共323例，结果报告如下：     

1063例STD门诊患者解脲支原体、沙眼衣原体与淋球菌感染情况分析

目的了解本地区STD门诊患者的解脲支原体、沙眼衣原体和淋球菌的感染情况。指导临床诊断、用药。方法采集女性宫颈口分泌物、男性尿道口分泌物分别做淋球菌培养、沙眼衣原体抗原检测和解脲支原体培养。结果1063例STD门诊患者中查出单一淋球菌感染208例,单一衣原体感染172例,单一解脲支原体感染358例,支原体、衣原体混合感染53例,淋球菌、支原体混合感染68例,淋球菌、衣原体感染60例,淋球菌、衣原体、支原体三重感染5例。结论混合感染率比较高,混合感染女性明显高于男性,支原体感染女性明显高于男性。     

428例泌尿生殖道淋球菌和支原体检测及药物敏感试验

目的:了解泌尿生殖道淋球菌与支原体感染状况及对抗生素的敏感性。方法:淋球菌采用巧克力培养基置于CO_2培养箱内培养,用纸片法进行药敏试验;用IST试剂盒进行支原体培养及分析其耐药性。结果:428例中,淋球菌阳性率6.54％,支原体总阳性率38.55％,UU、MH及UU MH混合感染率分别为32.48％、2.27％、2.80％。药敏试验表明:淋球菌对头孢噻肟钠、壮观霉素、阿奇霉素敏感,对青霉素、四环素耐药。支原体对阿奇霉素、左旋氧氟沙星、美满霉素、克拉霉素敏感,对四环素、红霉素耐药性较强。结论:对淋球菌支原体感染分析及耐药性检测,对指导临床治疗有重要意义。     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Self‐resolving superficial primary cutaneous mucormycosis in a 7‐week‐old infant

A 7‐week‐old girl, born at 30 weeks' gestational age, presented to clinic for evaluation of a crop of vesicular lesions that were noted after removal of a bandage that had been in place for 4 days. A punch biopsy of the lesion revealed fungal elements that were later identified as Rhizopus spp. The lesion began to self‐resolve, and no further treatment was needed, with full resolution of the lesion by 1 month after presentation. Clinicians should be aware of the variable presentations of mucormycosis and consider fungal infection in the differential diagnosis when evaluating vulnerable patients with skin eruptions.     

Multiple New-Onset Subcutaneous Nodules of the Upper Extremity Digits: Giant Cell Tumor of Tendon Sheath and Lipoma

A black woman with the concurrent onset of two subcutaneous nodules located on the digits of her upper extremities is described. Initially, a single systemic disorder was considered; yet, the lesions differed in morphology and consistency. Microscopic examination of the nodules showed a giant cell tumor of tendon sheath and a lipoma. Although Occam's “razor” suggests that multiple lesions in the same person are more likely to represent variable manifestations of a single disorder than several different diseases in that individual, the simultaneously appearing lesions in this patient represented two different conditions.